InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
May 05, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on...
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
April 28, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...
AREV Life Sciences Global Corporation announces engagement of TransBIOTech to facilitate preclinical therapeutic pipeline development
April 21, 2022 16:52 ET
|
AREV Life Sciences Global Corp.
VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) announced today its initial...
ECGI Approaching Key Strategic Milestones in the Cannabinoid Marketplace
March 29, 2022 08:30 ET
|
ECGI Holdings, Inc.
LOS ANGELES, March 29, 2022 (GLOBE NEWSWIRE) -- via InvestorWire - ECGI HOLDINGS INC. (OTC: ECGI) (“ECGI” or the “Company”), D/B/A Elite Cannabis Group Incorporated, a Nevada-based portfolio company...
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer
March 28, 2022 08:30 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the...
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
March 23, 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
CBD Pharmaceuticals (a subsidiary of Yuluka Health SAS) Signs Major Long-Term Seed Supply Agreements with Leading European Wholesalers to Start in the 2022 Calendar Year
March 22, 2022 16:51 ET
|
Yuluka Health Inc.
CALI, Colombia, March 22, 2022 (GLOBE NEWSWIRE) -- Yuluka Health SAS is pleased to announce the final stage of completion of its licensing and infrastructure upgrades of its subsidiary CBD...
InMed to Present at the 34th Annual Roth Conference
March 08, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
Vancouver, BC, March 08, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
UPDATE - Isracann Signs LOI to Acquire Natural Health Medicine Developer
February 24, 2022 16:09 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on...
Isracann Signs LOI to Acquire Natural Health Medicine Developer
February 23, 2022 08:30 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on...